Alkem Laboratories Limited
NSE: ALKEM BSE: ALKEM
NSE
5,704.00
79.00 (1.40%)
Prev Close
5625
Open Price
5635
Volume
53,084
Today Low / High
5622.5 / 5764.5
52 WK Low / High
4491.65 / 5933.5
Range
5,419 - 5,989
BSE
5,690.75
72.90 (1.30%)
Prev Close
5617.85
Open Price
5647
Volume
1,931
Today Low / High
5622.6 / 5760
52 WK Low / High
4498.9 / 5933
Range
5,406 - 5,975
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 5704 (target range: 5,419 - 5,989), reflecting a change of 79 (1.40444%). On the BSE, it is listed at 5690.75 (target range: 5,406 - 5,975), showing a change of 72.9 (1.29765%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
26 Feb
5,635.00
1.18%
25 Feb
5,508.50
2.11%
24 Feb
5,500.00
-0.08%
23 Feb
5,415.00
1.39%
20 Feb
5,330.00
1.16%
19 Feb
5,517.00
-2.54%
18 Feb
5,460.00
0.07%
17 Feb
5,500.00
-0.79%
16 Feb
5,431.00
0.91%
13 Feb
5,850.00
-7.65%
12 Feb
5,894.00
-0.40%
11 Feb
5,840.00
0.86%
10 Feb
5,750.00
1.07%
09 Feb
5,699.50
0.89%
06 Feb
5,683.00
0.02%
05 Feb
5,650.50
0.21%
04 Feb
5,678.00
-0.43%
03 Feb
5,714.00
-0.20%
02 Feb
5,616.00
-1.68%
01 Feb
5,690.00
-2.20%
30 Jan
5,690.00
-0.22%
29 Jan
5,750.00
-0.64%
Alkem Laboratories Limited Graph
Alkem Laboratories Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Alkem Laboratories Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 5,704.00, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 5,690.75 | 5,747.66 | 5,172.89 - 6,322.42 |
| 5,804.57 | 4,643.65 - 6,965.48 | ||
| 5,861.47 | 4,103.03 - 7,619.91 | ||
| Bearish Scenario | 5,690.75 | 5,633.84 | 5,070.46 - 6,197.23 |
| 5,576.94 | 4,461.55 - 6,692.32 | ||
| 5,520.03 | 3,864.02 - 7,176.04 |
Overview of Alkem Laboratories Limited
ISIN
INE540L01014
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
111,150
Market Cap
681,819,412,500
Last Dividend
51
Official Website
IPO Date
2015-12-23
DCF Diff
-3,283.97
DCF
8,985
Financial Ratios Every Investor Needs
Stock Dividend of ALKEM
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2026-02-20 | February 20, 26 | 43 | 43 | 2026-02-20 | 2026-03-06 | |
| 2025-08-08 | August 08, 25 | 8 | 8 | 2025-08-08 | 2025-09-24 | |
| 2025-02-14 | February 14, 25 | 37 | 37 | 2025-02-14 | 2025-02-28 | |
| 2024-08-09 | August 09, 24 | 5 | 5 | 2024-08-10 | 2024-09-29 | |
| 2024-02-16 | February 16, 24 | 35 | 35 | 2024-02-17 | 2024-03-01 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 12,964.52 Cr | 4,925.47 Cr | 8,039.05 Cr | 0.6201 | 562.00 Cr | 316.98 Cr | 2,184.23 Cr | 2,165.48 Cr | 181.11 | 3,005.89 Cr | 0.1670 |
| 2024-03-31 | 12,567.30 Cr | 7,928.65 Cr | 4,638.65 Cr | 0.3691 | 524.60 Cr | 302.90 Cr | 1,951.30 Cr | 1,795.77 Cr | 150.19 | 2,419.51 Cr | 0.1429 |
| 2023-03-31 | 11,599.26 Cr | 5,020.73 Cr | 6,578.53 Cr | 0.5672 | 541.14 Cr | 299.14 Cr | 1,366.83 Cr | 984.17 Cr | 82.31 | 1,722.55 Cr | 0.0848 |
| 2022-03-31 | 10,634.19 Cr | 4,283.29 Cr | 3,594.70 Cr | 0.3380 | 569.04 Cr | 247.58 Cr | 1,784.37 Cr | 1,645.62 Cr | 137.63 | 2,190.66 Cr | 0.1547 |
| 2021-03-31 | 8,822.72 Cr | 3,586.33 Cr | 5,142.07 Cr | 0.5828 | 533.65 Cr | 222.68 Cr | 1,671.42 Cr | 1,585.02 Cr | 132.57 | 2,175.60 Cr | 0.1797 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 304.14 Cr | 17,691.10 Cr | 5,257.47 Cr | 11,984.8700 Cr | 1,380.90 Cr | 1,076.76 Cr | 2,922.41 Cr | 2,931.87 Cr | 0.00 Cr | 21.95 Cr | 1,328.69 Cr | 3,964.9800 Cr |
| 2024-03-31 | 455.07 Cr | 15,574.90 Cr | 4,860.50 Cr | 10,312.0600 Cr | 1,418.41 Cr | 963.34 Cr | 2,661.18 Cr | 2,557.03 Cr | 112.29 Cr | 25.84 Cr | 413.40 Cr | 3,994.5500 Cr |
| 2023-03-31 | 273.80 Cr | 13,756.65 Cr | 4,321.65 Cr | 9,045.2900 Cr | 1,396.68 Cr | 1,122.88 Cr | 2,607.53 Cr | 2,513.55 Cr | 73.97 Cr | 8.80 Cr | 579.31 Cr | 3,707.1500 Cr |
| 2022-03-31 | 232.18 Cr | 14,069.19 Cr | 5,221.86 Cr | 8,637.9000 Cr | 2,668.19 Cr | 2,436.01 Cr | 3,005.53 Cr | 2,659.10 Cr | 72.87 Cr | 7.92 Cr | 928.85 Cr | 4,805.3400 Cr |
| 2021-03-31 | 174.22 Cr | 11,519.26 Cr | 3,961.25 Cr | 7,376.7300 Cr | 1,791.98 Cr | 1,617.76 Cr | 2,312.44 Cr | 2,658.16 Cr | 0.00 Cr | 8.83 Cr | -1,420.90 Cr | 3,604.0500 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1,912.8400 Cr | -1,298.7600 Cr | -810.9900 Cr | 1,237.2200 Cr | -186.4000 Cr | -120.0900 Cr | -675.6200 Cr | 2,527.0300 Cr | -194.1100 Cr | -504.6200 Cr | -261.2300 Cr |
| 2024-03-31 | 1,948.0700 Cr | -1,008.5000 Cr | -1,145.0100 Cr | 1,688.7800 Cr | -207.4900 Cr | 66.3100 Cr | -259.2900 Cr | 1,795.7700 Cr | -480.8900 Cr | -538.0400 Cr | -73.4000 Cr |
| 2023-03-31 | 1,682.5000 Cr | 112.8400 Cr | -1,760.8200 Cr | 1,449.5900 Cr | 41.6200 Cr | 273.8000 Cr | -232.9100 Cr | 1,304.7700 Cr | -1,278.4800 Cr | -529.5200 Cr | 473.4100 Cr |
| 2022-03-31 | 1,111.0200 Cr | -1,435.1300 Cr | 379.5700 Cr | 772.1400 Cr | 57.9600 Cr | 232.1800 Cr | -338.8800 Cr | 1,844.2800 Cr | 862.7800 Cr | -421.9100 Cr | -673.1400 Cr |
| 2021-03-31 | 1,264.9000 Cr | -998.5400 Cr | -271.7500 Cr | 1,069.9900 Cr | -1.7200 Cr | 174.2200 Cr | -194.9100 Cr | 1,842.1000 Cr | 139.6800 Cr | -334.7800 Cr | -497.7000 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 3,736.82 Cr | 2,089.23 Cr | 1,647.59 Cr | 0.4409 | 732.99 Cr | 636.02 Cr | 53.00 | 828.00 Cr | 0.1702 |
| 2025-09-30 | 4,000.99 Cr | 1,401.03 Cr | 2,599.96 Cr | 0.6498 | 827.16 Cr | 765.06 Cr | 63.99 | 1,024.46 Cr | 0.1912 |
| 2025-06-30 | 3,371.14 Cr | 1,171.16 Cr | 2,199.98 Cr | 0.6526 | 651.37 Cr | 664.26 Cr | 55.56 | 888.47 Cr | 0.1970 |
| 2025-03-31 | 3,143.75 Cr | 2,008.12 Cr | 1,135.63 Cr | 0.3612 | 308.04 Cr | 305.86 Cr | 25.58 | 537.25 Cr | 0.0973 |
| 2024-12-31 | 3,374.28 Cr | 1,204.33 Cr | 2,169.95 Cr | 0.6431 | 674.11 Cr | 625.82 Cr | 52.34 | 852.38 Cr | 0.1855 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 226.10 Cr | 4,925.94 Cr | 5,152.04 Cr | 3,101.82 Cr | 3,007.36 Cr | 12,126.05 Cr | 3,138.10 Cr | 20,287.45 Cr | 6,476.52 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 4,104.73 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -12,433.63 Cr |
| 2025-03-31 | 304.14 Cr | 4,195.63 Cr | 3,777.92 Cr | 2,475.29 Cr | 2,922.41 Cr | 10,945.82 Cr | 2,931.87 Cr | 17,691.10 Cr | 5,257.47 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 2,288.88 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -11,910.08 Cr |
| 2024-09-30 | 1,952.25 Cr | 336.63 Cr | 2,288.88 Cr | 2,512.80 Cr | 2,912.18 Cr | 11,109.28 Cr | 2,561.16 Cr | 17,117.03 Cr | 5,206.95 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 664.26 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 305.86 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 625.82 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 688.64 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 545.16 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,775.50 | ₹4,260,019,239,235.00 | ₹879,472.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,410.50 | ₹1,701,786,332,090.00 | ₹298,827.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,400.80 | ₹1,489,430,692,352.00 | ₹200,001.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,316.90 | ₹1,096,409,049,411.00 | ₹856,394.00 |
| Lupin Limited | LUPIN | ₹2,314.60 | ₹1,057,871,727,800.00 | ₹623,115.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹935.55 | ₹941,382,209,345.00 | ₹1,186,418.00 |
| Mankind Pharma Limited | MANKIND | ₹2,270.00 | ₹937,067,513,440.00 | ₹2,139,730.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,226.00 | ₹712,062,789,798.00 | ₹1,588,622.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,704.50 | ₹682,058,542,500.00 | ₹53,056.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,113.30 | ₹596,374,983,770.00 | ₹353,088.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,090.00 | ₹588,443,674,380.00 | ₹1,795,848.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,533.10 | ₹388,953,936,616.00 | ₹655,196.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,984.60 | ₹372,882,863,390.00 | ₹92,444.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹2,073.50 | ₹332,853,866,631.00 | ₹91,593.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,442.00 | ₹273,363,602,680.00 | ₹97,589.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,372.40 | ₹223,004,252,736.00 | ₹158,805.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,865.50 | ₹221,637,500,000.00 | ₹1,689.00 |
| Eris Lifesciences Limited | ERIS | ₹1,358.40 | ₹185,037,024,734.00 | ₹36,962.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹971.30 | ₹173,969,416,731.00 | ₹787,721.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,205.00 | ₹169,418,684,245.00 | ₹25,909.00 |
| Granules India Limited | GRANULES | ₹593.25 | ₹143,963,215,767.00 | ₹384,599.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹731.15 | ₹143,717,128,113.00 | ₹83,085.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹878.75 | ₹139,167,416,055.00 | ₹70,159.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,724.20 | ₹131,059,366,243.00 | ₹15,216.00 |
| Cohance Lifesciences Limited | COHANCE | ₹309.00 | ₹118,213,246,260.00 | ₹478,549.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹917.15 | ₹112,567,322,400.00 | ₹42,294.00 |
| Viyash Scientific Limited | VIYASH | ₹216.75 | ₹94,547,554,913.00 | ₹291,143.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,144.50 | ₹85,395,520,699.00 | ₹6,089.00 |
| Strides Pharma Science Limited | STAR | ₹862.50 | ₹79,498,965,825.00 | ₹125,351.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹482.35 | ₹73,848,777,676.00 | ₹66,263.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹339.00 | ₹66,302,235,624.00 | ₹455,053.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹717.40 | ₹65,030,365,846.00 | ₹57,985.00 |
| FDC Limited | FDC | ₹362.95 | ₹59,091,919,988.00 | ₹32,886.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹128.79 | ₹41,795,135,319.00 | ₹135,438.00 |
| Innova Captab Limited | INNOVACAP | ₹671.70 | ₹38,437,984,809.00 | ₹13,918.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹312.35 | ₹34,035,300,523.00 | ₹17,732.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹372.00 | ₹33,952,440,000.00 | ₹46,204.00 |
| Suven Life Sciences Limited | SUVEN | ₹147.50 | ₹33,552,415,000.00 | ₹161,364.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹629.95 | ₹31,950,500,195.00 | ₹73,886.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,910.00 | ₹31,589,518,650.00 | ₹3,085.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹282.30 | ₹28,309,751,444.00 | ₹30,273.00 |
Key Executives
President & Chief Medical Officer
Akhilesh D. Sharma
Gender: Not Specified
Year Born: 1969
Chief Executive Officer
Vikas Gupta
Gender: Not Specified
Year Born:
Executive Chairman
Basudeo Narian Singh
Gender: male
Year Born: 1941
Executive Director
Mritunjay Kumar Singh
Gender: male
Year Born: 1963
Executive Director
Srinivas Singh
Gender: male
Year Born: 1988
Executive Director
Madhurima Singh
Gender: female
Year Born: 1965
Chief Financial Officer & President of Finance
Nitin Agrawal
Gender: male
Year Born:
President & Global HR Head
Rajorshi Ganguli
Gender: male
Year Born: 1971
MD & Executive Director
Sandeep Derjit Singh
Gender: male
Year Born: 1982
President & Global Quality Head
Shirish Purushotham Ambulgekar
Gender: male
Year Born:
FAQs about Alkem Laboratories Limited
Who is the CEO of the company?
The CEO is Vikas Gupta.
What is the current market price of the stock?
The current price is ₹5,702.50.
What is the 52-week price range?
The range is ₹4491.65-5933.5.
What is the market capitalization of the company?
The market capitalization is ₹68,181.94 crores.
What is the dividend yield?
The dividend yield is 0.89%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 28.86.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Alkem Laboratories Limited (ISIN: INE540L01014) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹68,181.94 crores and an average daily volume of 111,150 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹51.